endTB aims to find shorter, less toxic and more effective treatments for ‘multidrug-resistant TB’ (MDR-TB) through:

  • access to new drugs
  • two clinical trials
  • advocacy at national and global levels.

Covering 18 countries, the project is a partnership between Partners In Health, Médecins Sans Frontières, Interactive Research & Development and financial partners Unitaid and the Transformational Investment Capacity (TIC) of MSF. 

You can contact us, or follow us on Twitter.

Watch the two-minute animation

The endTB-Q clinical trial results will be presented at the Union Conference in Bali

Union Conference 2024

 

We are happy to announce that the endTB-Q clinical trial results will be presented for the first time at the Union World Conference on Lung Health, in Bali, Indonesia, November 12-16.

Read more 

endTB participant

Major advance in the fight against MDR-TB: four new short and effective treatments approved by the WHO

Paris, 19 August 2024 - In a rapid communication, the World Health Organization (WHO) recommended 3 new regimens for multidrug- or rifampicin-resistant tuberculosis (MDR/RR-TB), which were studied in the endTB clinical trial. This is a breakthrough in the fight against MDR-TB worldwide.

Read more here

endTB clinical trial results - VIDEO

The endTB clinical trial results are out! This landmark trial offers multiple new shortened, all-oral drug regimens to treat adults and children with MDR-TB. 

The video is now also available with Spanish, French and Russian subtitles.

Read our press release and more here

 

PIH MSF MSF Unitaid: Save Lives Faster Médecins Sans Frontières (MSF) Transformational Investment Capacity (TIC) logo